In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Miltenyi Biotec B.V. & Co. KG

https://www.miltenyibiotec.com/UN-en/

Latest From Miltenyi Biotec B.V. & Co. KG

EMA Accepts First Diabetes Drug Onto PRIME

Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.

Drug Review Research & Development

Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health

This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.

Executive Changes BioPharmaceutical

Tech Transfer Roundup: UM Ventures' Deal-Making Priority Is Flexibility

Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.

Deals StartUps and SMEs

Deal Watch: Takeda Continues Transaction Spree With Four More Deals

Takeda's recent deals include a license in Asian for Tesaro's PARP inhibitor Zejula. Meanwhile, Japanese rival Mitsubishi Tanabe is paying roughly $1bn to acquire Israel's NeuroDerm.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register